American Well Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by American Well Corporation on April 2, 2024. The filing addresses a regulatory notice received from the New York Stock Exchange (NYSE) regarding the Company's compliance with continued listing standards.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures. The only quantitative metric disclosed is the stock price performance triggering the listing notice: the average closing price of the Class A Common Stock was less than $1.00 per share over a consecutive 30 trading-day period.
Material Changes
- Listing Compliance Notice: The Company received notice from the NYSE of non-compliance with Section 802.01C of the Listed Company Manual due to the low stock price.
- Operational Impact: The notice has no immediate impact on the listing of the Common Stock or the Company's business operations and reporting obligations.
Outlook, Management Commentary, and Risks
Cure Period: The Company has a six-month period from the receipt of the notice to regain compliance with the minimum price criteria.
Compliance Strategy: The Company has confirmed its intent to regain compliance, potentially by effecting a reverse stock split. This action is subject to board approval and stockholder approval at the upcoming 2024 annual meeting.
Compliance Criteria: To regain compliance, the Common Stock must have a closing price of at least $1.00 per share and an average closing price of at least $1.00 per share over the 30 trading-day period ending on the last trading day of any calendar month during the cure period.
Investor Verification Checklist
- Verify the current trading price and 30-day average of American Well Corp. (AMWL) stock.
- Monitor the Company's 2024 annual meeting schedule for stockholder approval of a potential reverse stock split.
- Track the six-month cure period deadline to ensure the Company regains compliance with NYSE listing standards.
- Review the attached press release (Exhibit 99.1) for additional management commentary on the stock price decline.